RXRX241213P6500
- 0.03
- -0.01-25.00%
Recursion Pharmaceuticals Newsroom
Needham Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Maintains Target Price $11
Promising Developments and Positive Outlook for Recursion Pharmaceuticals Drive Buy Rating
Recursion Pharmaceuticals Analyst Ratings
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $11 Price Target
TD Cowen Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating
TD Cowen Keeps Their Hold Rating on Recursion Pharmaceuticals (RXRX)
BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Maintains Target Price $12
Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Recursion Pharmaceuticals (RXRX) and AN2 Therapeutics, Inc. (ANTX)
Hold Rating Recommended for Recursion Pharmaceuticals Post-Merger With Exscientia: Upside Potential Amidst Clinical Uncertainties
BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Cuts Target Price to $12
KeyBanc Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Maintains Target Price $12
Recursion Pharmaceuticals Analyst Ratings
Needham Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Maintains Target Price $11
TD Cowen Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating
Needham Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Maintains Target Price $11
Buy Rating for Recursion Pharmaceuticals Amid Strategic Merger and Innovative Drug Development
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $11 Price Target
Recursion Pharmaceuticals Analyst Ratings
TD Cowen Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating
TD Cowen Reaffirms Their Hold Rating on Recursion Pharmaceuticals (RXRX)